Stay updated with breaking news from Primary Outcomes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investigators believe targeted immunomodulation with SEL-212 may have the potential to introduce a new uricase-based therapy for patients with gout refractory to conventional treatment.
Late-breaking trials will be presented during the main sessions and highlighted during press conferences scheduled for Oct. 24, 25 and 26
/PRNewswire/ -- The "Global Idiopathic Pulmonary Fibrosis Market, By Therapy, Estimation & Forecast, 2017-2030" report has been added to...
/PRNewswire/ -- The "Global Idiopathic Pulmonary Fibrosis Market, By Therapy, Estimation & Forecast, 2017-2030" report has been added to...